MAYNF
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.18 | $212M | -$9M |
| 2025 Q4 | -0.89 | $195M | $25M |
| 2024 Q2 | -0.25 | $213M | -$20M |
| 2024 Q4 | -1.18 | $200M | $9M |
| 2023 Q2 | -0.87 | $188M | -$41M |
| 2023 Q4 | -2.06 | $82M | $12M |
| 2022 Q2 | -1.64 | $101M | -$275M |
| 2022 Q4 | -2.41 | $228M | -$18M |